Walgreens Boots Alliance — Q2 2024 Earnings Presentation
38 slides from Walgreens Boots Alliance's earnings presentation, Mar 28, 2024
Slide 1: Second Quarter Fiscal 2024 Results
Second Quarter Fiscal 2024 Results March 28, 2024 © 2024 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 2: Safe Harbor and Non-GAAP
Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat
Slide 3: Another quarter of execution, advancing FY24 goals
Another quarter of execution, advancing FY24 goals • 2Q operational results in line with expectations − Execution and cost discipline in U.S. Retail Pharmacy − Continued strong performance in International − First quarter of positive adj. EBITDA1 in U.S. Healthcare − Adj. EPS1 beat includes $0.36 be
Slide 4: Executive team now solidified to lead WBA
Executive team now Tim Wentworth solidified to lead WBA Chief Executive Officer Business Unit Leadership Tracey Brown Rick Gates Mary Langowski Ornella Barra Executive Vice Senior Vice President Executive Vice President Chief Operating Officer, President, President, and Chief Pharmacy and President,
Slide 5: Performance across business segments in line with expectations
Performance across business segments in line with expectations U.S. Retail Pharmacy • Comp scripts excluding immunizations +2.9% vs. 2Q23, maintaining market share, strong performance in Execution in pharmacy and pharmacy services cost savings • Expanding role of and advocating for pharmacists: prov
Slide 6: Mary Langowski
Mary Langowski Executive Vice President and President, U.S. Healthcare © 2024 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 7: WBA 2Q24 Financial Highlights
Reported Fx Constant Fx 2Q24 $ in millions (except EPS) B/(W) vs. 2Q23 B/(W) vs. 2Q23 Sales $37,052 + 6.3% + 5.7% Operating Income GAAP ($13,171) ($13,368) WBA 2Q24 Adjusted1 $900 (25.9)% (26.5)% Financial Net Earnings GAAP ($5,908) ($6,610) Highlights Adjusted1 $1,036 + 3.5% + 3.0% EPS GAAP ($6.85)
Slide 8: WBA 1H24 Financial Highlights
Reported Fx Constant Fx 1H24 $ in millions (except EPS) B/(W) vs. 1H23 B/(W) vs. 1H23 Sales $73,760 + 8.1% + 7.2% Operating Income GAAP ($13,209) ($7,255) Adjusted1 $1,588 (28.8)% (29.5)% WBA 1H24 Net Earnings GAAP ($5,975) ($2,957) Financial Adjusted1 $1,607 (19.8)% (20.4)% Highlights EPS GAAP ($6.
Slide 9: U.S. Retail Pharmacy Financials
2Q24 B/(W) vs. 2Q23 1H24 B/(W) vs. 1H23 $ in millions Sales $28,861 4.7% $57,805 5.5% Adj. gross profit1 $5,570 (4.8)% $11,064 (5.9)% U.S. Retail Adj. SG&A % of sales1 17.0% + 0.7%p 17.0% + 1.0%p Pharmacy Adj. operating income1 $752 (29.5)% $1,446 (33.4)% Financials Adj. operating margin1,2 2.3% (1.
Slide 10: U.S. Pharmacy
2Q24 2Q24 1H24 1H24 2Q24 vs. 2Q23 | 1H24 vs. 1H23 Total Comparable Total Comparable Pharmacy sales + 8.2% + 8.7% + 9.5% + 10.9% Prescriptions + 2.6% + 2.7% + 1.3% + 2.0% Prescriptions ex. +2.7% + 2.9% + 1.6% + 2.3% Immunizations U.S. Pharmacy • Comp pharmacy sales +8.7% primarily due to brand inflat
Slide 11: U.S. Retail
2Q24 1H24 2Q24 vs. 2Q23 | 1H24 vs. 1H23 Total retail sales (4.5)% (5.3)% Comparable retail sales (4.3)% (4.6)% U.S. Retail • Comp retail sales (4.3)%, primarily due to a challenging retail environment, channel shift, and a weaker respiratory season, including: − (170) bps impact from lower seasonal
Slide 12: International Financials
Constant Fx1 Constant Fx1 2Q24 1H24 $ in millions B/(W) vs. 2Q23 B/(W) vs. 1H23 Sales $6,022 + 3.2% $11,854 + 3.8% Adj. gross profit1 $1,287 + 3.2% $2,498 + 5.0% Adj. SG&A % of sales1 17.3% (2.2)%p 17.8% (1.3)%p International Adj. operating income1 $245 (32.4)% $387 (20.6)% Financials Adj. operating
Slide 13: Boots UK Financials
2Q24 1H24 2Q24 vs. 2Q23 | 1H24 vs. 1H23 (constant Fx) Pharmacy comp. sales + 1.7% + 1.2% Retail comp. sales + 5.9% + 7.6% Boots UK • Strong retail comp sales +5.9% with growth across all categories, on top of +16.0% in Financials the prior year − Growth in Destination Health & Beauty, Flagship, and
Slide 14: U.S. Healthcare Financials
2Q24 B/(W) vs. 2Q23 1H24 B/(W) vs. 1H23 $ in millions Sales $2,176 + $542 $4,107 + $1,484 Adj. gross profit1 $211 + $101 $357 + $204 Adj. SG&A1 ($244) + $25 ($486) ($22) Adj. operating loss1 ($34) + $126 ($129) + $182 U.S. Healthcare Adj. EBITDA1 $17 + $127 ($22) + $211 Financials • 2Q sales led by
Slide 15: Cash Flow
B/(W) 1H24 $ in millions vs. 1H23 Operating cash flow ($918) ($2,157) Cash capital expenditure ($858) $250 Free cash flow1,2 ($1,397) ($1,957) Cash Flow • Operating cash flow negatively impacted by $699M in payments related to legal matters, $379M Boots Pension Plan Annuity premium contributions, an
Slide 16: Narrowing FY24 adj. EPS guidance to $3.20 - $3.35
Narrowing FY24 adj. EPS1 guidance to $3.20 - $3.35 • Guidance incorporates challenging retail environment in the U.S., lower sale-leaseback contributions and Cencora share sales, offset by execution in pharmacy services and a lower adjusted effective tax rate1 • Continuing to expect U.S. Healthcare
Slide 17: Cost savings and U.S. Healthcare expected to benefit 2H FY24
Cost savings and U.S. Healthcare expected to benefit 2H FY24, offset by early wind-down of sale-leaseback and incentive accrual Key YOY considerations in 2H 2H Drivers 2H 2023 adj. EPS1 $1.66 • U.S. Healthcare: On track to +$165M adj. EBITDA1 at midpoint of guidance range, driven by VillageMD and Sa
Slide 18: Pharmacy performance and U.S. Healthcare fueled first half results
Pharmacy performance and U.S. Healthcare fueled first half results, continued focus on capital efficient growth • Delivering two quarters of execution despite challenging retail environment • Building out an asset light health services strategy rooted in our retail pharmacy footprint to deliver care
Slide 19: Q&A
Q&A 1. Refer to safe harbor and non-GAAP disclosure on slide 2, © 2024 Walgreens Boots Alliance, Inc. All rights reserved. endnotes on slide 20, and reconciliations on slides 22-37 19
Slide 20: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 21: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 22: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,
Slide 23: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING INCOME, ADJUSTED EBITDA and ADJUSTED EBITDAR As Reported Twelve months ended February 29, 2024 Net loss (GAAP) $ (12,856) Po
Slide 24: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa
Slide 25: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET (LOSS) EARNINGS TO ADJUSTED NET EARNINGS AND DILUTED NET (LOSS) EARNINGS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE Three months ended Change
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET (LOSS) EARNINGS TO ADJUSTED NET EARNINGS AND DILUTED NET (LOSS) EARNINGS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Acquisition-related amortization includes amortization of acquisition-related intangible assets, inventory valuation adjustments and stock-based compensation fair valu
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 14 Due to the anti-dilutive effect resulting from periods where the Company reports a net loss, the impact of potentially dilutive securities on the per share amounts ha
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 29, 2024 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 28,861
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,577
Slide 31: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 29, 2024 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 57,805 $
Slide 32: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 54,781 $
Slide 33: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating (loss) income for U.S. Retail Pharmacy includes equity earnings in Cencora. As a result of the two-month reporting lag, operating income for the three and si
Slide 34: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR U.S. HEALTHCARE SEGMENT Three months ended Six months ended February 29, 2024 February 28, 2023 February 29, 2024 Feb
Slide 35: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN CENCORA Three months ended Six months ended February 29, 2024 February 28, 2023 February 29, 2024 February 28, 2023 Equity earnings in C
Slide 36: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended February 29, 2024 Three months ended February 28, 2023 (Loss) Earnings Earnings before before income Income
Slide 37: Free cash flow
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended Six months ended February 29, 2024 February 28, 2023 February 29, 2024 February 28, 2023 Net cash (used for) provided by
Slide 38: Sale-Leaseback Financial Information
Sale-Leaseback Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Sale-leaseback financial information Three months ended Six months ended February 29, 2024 Change vs. 2Q23 February 29, 2024 Change vs. 1H23 U.S. Retail Pharmacy Ga
Walgreens Boots Alliance — Q2 2024 Earnings Presentation on 6ix